Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01350388 · ClinicalTrials.gov registry record · NA
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
A NA study, sponsored by University of Utah.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT01350388 is a NA study that has completed, run by University of Utah. The registered enrollment target is 80 participants.
The verdict
NCT01350388, a NA study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of uric acid with febuxostat it is hypothesized that the levels of oxidative stress in adipose tissue (obtained by fat biopsy) will decrease. Primary aims of the study are to determine whether febuxostat therapy in overweight or obese, diabetic patients with stage 3 Chronic Kidney Disease (CKD) and high serum uric acid levels 1. will affect adipose tissue concentrations of thiobarbituric acid reactive substance (TBARS), a marker of oxidative stress 2. will affect adipose tissue expression and concentrations of adiponectin; and 3. will affect urinary concentrations of transforming growth factor (TGF)- B1.
Interventions
- DRUG Placebo
- DRUG Febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01350388
The ClinicalTrials.gov registry entry for NCT01350388 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01350388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01350388 about?
NCT01350388 is a clinical study titled "Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease". Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of uric acid with febuxostat it is h...
What is the current status of trial NCT01350388?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2011-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01350388?
The interventions under investigation include: Placebo (DRUG), Febuxostat (DRUG).
Who is sponsoring clinical trial NCT01350388?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.